South Korea · Delayed Price · Currency is KRW Hanall Biopharma Statistics
Total Valuation
KRX:009420 has a market cap or net worth of KRW 1.64 trillion. The enterprise value is 1.63 trillion.
| Market Cap | 1.64T |
| Enterprise Value | 1.63T |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:009420 has 50.75 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 50.75M |
| Shares Outstanding | 50.75M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 13.85% |
| Float | 34.44M |
Valuation Ratios
The trailing PE ratio is 735.20 and the forward PE ratio is 283.25.
| PE Ratio | 735.20 |
| Forward PE | 283.25 |
| PS Ratio | 10.94 |
| PB Ratio | 10.52 |
| P/TBV Ratio | 16.88 |
| P/FCF Ratio | 132.70 |
| P/OCF Ratio | 119.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 229.94, with an EV/FCF ratio of 132.12.
| EV / Earnings | 731.99 |
| EV / Sales | 10.89 |
| EV / EBITDA | 229.94 |
| EV / EBIT | n/a |
| EV / FCF | 132.12 |
Financial Position
The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.50 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 0.11 |
| Interest Coverage | 50.04 |
Financial Efficiency
Return on equity (ROE) is 1.37% and return on invested capital (ROIC) is 1.49%.
| Return on Equity (ROE) | 1.37% |
| Return on Assets (ROA) | 1.21% |
| Return on Invested Capital (ROIC) | 1.49% |
| Return on Capital Employed (ROCE) | 2.40% |
| Revenue Per Employee | 493.71M |
| Profits Per Employee | 7.35M |
| Employee Count | 304 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.04 |
Taxes
In the past 12 months, KRX:009420 has paid 1.35 billion in taxes.
| Income Tax | 1.35B |
| Effective Tax Rate | 37.63% |
Stock Price Statistics
The stock price has decreased by -10.69% in the last 52 weeks. The beta is 0.80, so KRX:009420's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -10.69% |
| 50-Day Moving Average | 29,400.00 |
| 200-Day Moving Average | 31,328.50 |
| Relative Strength Index (RSI) | 57.68 |
| Average Volume (20 Days) | 413,332 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:009420 had revenue of KRW 150.09 billion and earned 2.23 billion in profits. Earnings per share was 44.00.
| Revenue | 150.09B |
| Gross Profit | 79.86B |
| Operating Income | 3.92B |
| Pretax Income | 3.58B |
| Net Income | 2.23B |
| EBITDA | 7.21B |
| EBIT | 3.92B |
| Earnings Per Share (EPS) | 44.00 |
Balance Sheet
The company has 8.54 billion in cash and 1.37 billion in debt, giving a net cash position of 7.16 billion or 141.17 per share.
| Cash & Cash Equivalents | 8.54B |
| Total Debt | 1.37B |
| Net Cash | 7.16B |
| Net Cash Per Share | 141.17 |
| Equity (Book Value) | 156.11B |
| Book Value Per Share | 3,075.70 |
| Working Capital | 40.56B |
Cash Flow
In the last 12 months, operating cash flow was 13.79 billion and capital expenditures -1.42 billion, giving a free cash flow of 12.37 billion.
| Operating Cash Flow | 13.79B |
| Capital Expenditures | -1.42B |
| Free Cash Flow | 12.37B |
| FCF Per Share | 243.79 |
Margins
Gross margin is 53.21%, with operating and profit margins of 2.61% and 1.49%.
| Gross Margin | 53.21% |
| Operating Margin | 2.61% |
| Pretax Margin | 2.39% |
| Profit Margin | 1.49% |
| EBITDA Margin | 4.80% |
| EBIT Margin | 2.61% |
| FCF Margin | 8.24% |
Dividends & Yields
KRX:009420 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.12% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.14% |
| FCF Yield | 0.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.
| Last Split Date | Apr 28, 2006 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
KRX:009420 has an Altman Z-Score of 31.94 and a Piotroski F-Score of 6.
| Altman Z-Score | 31.94 |
| Piotroski F-Score | 6 |